The safety and efficacy of Yokukansan in treating neuropsychiatric symptoms of patients with Fronto-Temporal Lobar Degeneration (FTLD) - The safety and efficacy of Yokukansan in treating neuropsychiatric symptoms of patients with Fronto-Temporal Lobar

Ehime University Graduate School of Medicine0 个研究点目标入组 20 人开始时间: 2009年4月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with concomitant diagnosis of malignant cancer. 2) Patients with concomitant diagnosis o sevious heart, liver, lung or kidney disease, blood disorders, or other life-threatening diseases. 3) Ptients with other forms of dementia (AD, VD, DLB) besides Fronto-Temporal Degeneration (FTLD) 4) Patients who fail to meet the DSM-IV diagnostic criteria for our study, but show symptoms of BPSD due to other concomitant neurodegerative disease, Scizophrenia, Bipolar disorder, Major depressive disorder or other psychiatric disorders. 5) Patients with delirium due to alcohol or drug addicution, metabolic poisoning, or inflammatory disease. 6) Patients who are unable to take oral medications. 7) Patients who altered their dosage or method of administration of SSRI, 8 weeks before the start of the study. 8) Ptients who took long acting antipsychotic durgs (such as haloperidol decanoate) 4 weeks before the start of treatment. 9) Patients who are determined as unfit for the study by attending physicians for reasons other than those stated above.

发起方

Ehime University Graduate School of Medicine